Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Overland Park, Kansas Clinical Trials

A listing of Overland Park, Kansas clinical trials actively recruiting patient volunteers.

RESULTS

Found (54) clinical trials

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

Functional MR is a frequent outcome of ischemic heart disease or dilated cardiomyopathy. Patients with functional MR generally have normal valvular structures complicated by left ventricular dysfunction. Left ventricular dysfunction will often create geometric distortions that prevent complete leaflet coaptation, rendering the valve incompetent. Changes that will induce functional MR ...

Phase

0.81 miles

Learn More »

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. ...

Phase

1.88 miles

Learn More »

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

If participants meet all the criteria, their involvement in the study (Phases 1 and 2 described below) will last for 10-13 weeks. Participants will be asked to stay at the research site for a minimum of 2 nights on 4 separate weeks and will have 22 office visits During that ...

Phase

1.88 miles

Learn More »

Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes

This study will be a randomized, two-part, 3-way crossover designed to evaluate the abuse liability, pharmacokinetics (PK), and product use behavior associated with study products, including VLN cigarettes, subjects' own-brand cigarettes, and nicotine polacrilex gum in healthy adult male and female exclusive smokers. Subjects will participate in a standard Screening ...

Phase

1.88 miles

Learn More »

4-Week Multiple-dose Dose-escalating Study In Patients With Type 2 Diabetes

This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.

Phase

1.88 miles

Learn More »

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own. The study also looks at how the study medicines behave in participant's body and how they are removed from ...

Phase

1.88 miles

Learn More »

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users

Phase

1.88 miles

Learn More »

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

The study is testing a new medicine for weight control in people with overweight or obesity. The aim of the study is to find out how safe the study medicine is and how it works in the body. Participants will either get NNC9204-1706 (the new study medicine) or placebo (a ...

Phase

1.88 miles

Learn More »

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Indoleamine 2,3 dioxygenase-1 (IDO1) is a target of cancer immunotherapy. Epacadostat (INCB24360) is an oral IDO1 inhibitor. IDO1 activation blocks T-cell activation, enhances T-cell apoptosis and promotes the differentiation of nave T cells to regulatory T cells (Tregs). Preclinical findings suggest that IDO1 is critical for cancers to evade immune ...

Phase

2.1 miles

Learn More »

Safety Study of LLF580 in Obese Volunteers

The purpose of the study is to evaluate the safety and tolerability of multiple doses of LLF580 administered subcutaneously over 3 months in obese subjects. In addition, the study will also determine early efficacy signals in various metabolic diseases associated with elevated triglycerides and/or obesity.

Phase

2.49 miles

Learn More »